Wells Fargo Maintains Equal-Weight on Jazz Pharmaceuticals, Lowers Price Target to $120
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal maintains an Equal-Weight rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) but lowers the price target from $140 to $120.
August 01, 2024 | 1:42 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Wells Fargo analyst Mohit Bansal maintains an Equal-Weight rating on Jazz Pharmaceuticals but lowers the price target from $140 to $120.
The lowered price target from $140 to $120 by Wells Fargo suggests a less optimistic outlook for Jazz Pharmaceuticals, which could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100